COVIRAP diagnostic technology
IIT Kharagpur has successfully commercialised its flagship healthcare product COVIRAP the novel diagnostic technology to zero on infectious diseases including COVID-19, the institute said on 21 April 2021. The product, developed by lead researchers Professor Suman Chakraborty, Dr Arindam Mondal and their research group, has been licensed for commercialisation to the Rapid Diagnostic Group of Companies, India and Bramerton Holdings LLC, USA.
- A virtual press meet was organised on 21 April 2021 by the institute in which the researchers were present along with the institute director to make the announcement.
- The above move has taken place at a critical juncture when the recent spurt in COVID-19 infection, commonly known as the second wave, has been threatening to spread more rapidly than ever before.
- Moreover, the commercialisation of COVIRAP will initiate complete indigenisation and availability of a large range of affordable healthcare products in the Indian market as well as deep trenches of a large global market that is literally starving for the need of such technology.
- Rapid Diagnostic has also initiated adapting the COVIRAP technology platform for COVID-19 and tuberculosis, in collaboration with IIT Kharagpur.
- The kit has also been supplemented with a free smartphone app to facilitate unambiguous results interpretation and automated dissemination to the patients.
- The researchers claimed COVIRAP test overcomes several potential bottlenecks faced by similar other tests in the past, for instance, poor performance outside highly controlled laboratory and lack of simple, affordable, yet generic and universal instrument that may be used for home-based testing and community healthcare for a wide variety of infectious and non-infectious diseases.
- Commercialisation and use in the USA and Europe under the Emergency Use Authorization (EUA) process are currently underway.